Cargando…
VCP/p97, a pleiotropic protein regulator of the DNA damage response and proteostasis, is a potential therapeutic target in KRAS-mutant pancreatic cancer
We and others have recently shown that proteins involved in the DNA damage response (DDR) are critical for KRAS-mutant pancreatic ductal adenocarcinoma (PDAC) cell growth in vitro. However, the CRISPR-Cas9 library that enabled us to identify these key proteins had limited representation of DDR-relat...
Autores principales: | Lee, Ye S., Klomp, Jennifer E., Stalnecker, Clint A., Goodwin, Craig M., Gao, Yanzhe, Droby, Gaith N., Vaziri, Cyrus, Bryant, Kirsten L., Der, Channing J., Cox, Adrienne D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10010283/ https://www.ncbi.nlm.nih.gov/pubmed/36923647 http://dx.doi.org/10.18632/genesandcancer.231 |
Ejemplares similares
-
The coordinated action of VCP/p97 and GCN2 regulates cancer cell metabolism and proteostasis during nutrient limitation
por: Parzych, Katarzyna, et al.
Publicado: (2019) -
Valosin-containing protein (VCP/p97) inhibitors relieve Mitofusin-dependent mitochondrial defects due to VCP disease mutants
por: Zhang, Ting, et al.
Publicado: (2017) -
A Dynamic molecular basis for malfunction in disease mutants of p97/VCP
por: Schuetz, Anne K, et al.
Publicado: (2016) -
CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment
por: Klomp, Jennifer E., et al.
Publicado: (2021) -
Role of p97/VCP (Cdc48) in genome stability
por: Vaz, Bruno, et al.
Publicado: (2013)